NeuroDerm’s Infusion System Delivers Clinically Significant Levodopa Levels in Parkinson’s Patients

Oral administration of drugs for Parkinson’s disease is regarded as the “gold standard” treatment. Now an Israeli company, NeuroDerm, Ltd is touting its subcutaneously administered Levodopa/Carbidopa (LD/CD) therapy which it says has delivered clinically-significant plasma levodopa levels, the main therapeutic objective.


Levodopa/Carbidopa is a primary tool in the treatment of patients with severe Parkinson’s disease, specifically in the management of motor complications. Indeed virtually all patients diagnosed with Parkinson’s disease will require levodopa at some point over the course of their treatment for the disease, and 70% to 80% of patients receive the drug at any given point in time. However, levodopa is limited by its short half-life. Approximately three to four hours after a single dose, almost none of the drug remains in the plasma. In addition, levodopa suffers from low absorption when administered orally, with only about 30% of the levodopa entering the blood stream.

NeuroDerm’s high dose infusion system, ND0612H, is intended to maintain high, consistent and stable levodopa plasma levels and a newly presented poster suggests it may provide an effective therapeutic alternative in most patients to the current treatment options that require surgery. In this poster additional statistical analyses were presented that reinforce the marked reduction of fluctuations in levodopa plasma levels and enhance the good safety and tolerability profile.

The poster presentation, “Stable levodopa plasma levels with ND0612 (LD/CD for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fluctuations,” has been selected as part of the 19th International Congress of Parkinson’s Disease and Movement Disorders Blue Ribbon Highlights Session, in San Diego. Chosen by a panel of experts from nearly 1,500 poster presentations, the Blue Ribbon Session provides a critical review of the best poster presentations, highlighting relevance, novelty and quality of both clinical data and basic research, according to the International Parkinson and Movement Disorder Society. The presentation had previously been accepted as a late-breaking poster.

Company comments

“Being selected to the Blue Ribbon Highlights Session is an exceptional honor for NeuroDerm as it underscores peer acknowledgement that NeuroDerm’s clinical results with its lead product candidates represent the best and most exciting work at this conference this year, and that NeuroDerm’s product candidates may lead to future breakthroughs in the treatment of Parkinson’s disease,” said Oded Lieberman, PhD, MBA, CEO. “More importantly, the data presented at this meeting emphasizes NeuroDerm’s potential to offer greatly improved future treatment options, including the prospect of an effective, non-surgical treatment alternative for advanced patients that currently face only limited, highly-invasive treatment options, condemning many of them to a debilitating and devastating life with Parkinson’s disease.”

Source: NeuroDerm Ltd


Share your thoughts

Your email address will not be published. Required fields are marked *